Thera-SAbDab

ROZANOLIXIZUMAB

> Structural Summary

Therapeutic	Rozanolixizumab
Target	FCGRT
Heavy Chain	EVPLVESGGGLVQPGGSLRLSCAVSGFTFSNYGMVWVRQAPGKGLEWVAYIDSDGDNTYYRDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCTTGIVRPFLYWGQGTLVTVSS
Light Chain	DIQMTQSPSSLSASVGDRVTITCKSSQSLVGASGKTYLYWLFQKPGKAPKRLIYLVSTLDSGIPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQGTHFPHTFGQGTKLEIK
100% seqID Fv Structure	6fgb [Fvs: HL]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	6fgb [Fvs: HL]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G4
Highest Clinical Trial (June '19)	Phase-III
Estimated Status (June '19)	Active
Recorded Developmental Technology	na
INN Year Proposed	2016
INN Year Recommended	2017
Companies Involved	UCB
Conditions Approved	na
Conditions Active	Chronic inflammatory demyelinating polyradiculoneuropathy, Idiopathic thrombocytopenic purpura, Myasthenia gravis
Conditions Discontinued	Immunological disorders
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]